Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study
Many patients require osimertinib dose reduction due to adverse events, but this process does not adversely affect the drug efficacy.
Authors
- Kiyotaka Yoh
- Kohei Uemura
- Kazuma Kishi (ORCID: https://orcid.org/0000-0002-6801-0147)
- Nobuyasu Awano (ORCID: https://orcid.org/0000-0002-1438-4880)
- Go Naka (ORCID: https://orcid.org/0000-0002-3804-0898)
- Kageaki Watanabe (ORCID: https://orcid.org/0000-0002-8420-5606)
- Yukio Hosomi (ORCID: https://orcid.org/0000-0002-3849-5905)
- Kazuhiro Usui (ORCID: https://orcid.org/0000-0002-4492-9327)
- Hideo Kunitoh
- Shu Tamano
Institutions
- Nihon University (JP)
- Toho University (JP)
- Tokyo University of Information Sciences (JP)
- NTT Medical Center (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- National Center for Global Health and Medicine (JP)
- Toho University Omori Medical Center (JP)
- Japanese Red Cross Medical Center (JP)
- National Cancer Center Hospital East (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1093/jjco/hyae173
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26